PPAR γ agonist rosiglitazone suppresses renal mPGES-1/PGE2 pathway in db/db mice

PPAR Research

Volumn , Issue , 2013, Pages

  Sun, Ying ^a,b   Jia, Zhanjun ^b   Liu, Gang ^b   Zhou, Li ^b   Liu, Mi ^b   Yang, Baoxue ^a   Yang, Tianxin ^b,c  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; CYCLOOXYGENASE 2 INHIBITOR; MPGES 1 PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTANOID; PROTEIN; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL PATHWAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; GLOMERULAR DYSFUNCTION; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; TISSUE LEVEL;

EID: 84894835909     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2013/612971     Document Type: Article

References (45)

1. Craven P. A., DeRubertis F. R., Role for local prostaglandin and thromboxane production in the regulation of glomerular filtration rate in the rat with streptozocin-induced diabetes. Journal of Laboratory and Clinical Medicine 1989 113 6 674 681 2-s2.0-0024361265 (Pubitemid 19151675)
2. DeRubertis F. R., Craven P. A., Eicosanoids in the pathogenesis of the functional and structural alterations of the kidney in diabetes. The American Journal of Kidney Diseases 1993 22 5 727 735 2-s2.0-0027433788 (Pubitemid 23330945)
3. Ishibashi R., Tanaka I., Kotani M., Muro S., Goto M., Sugawara A., Mukoyama M., Sugimoto Y., Ichikawa A., Narumiya S., Nakao K., Roles of prostaglandin E receptors in mesangial cells under high-glucose conditions. Kidney International 1999 56 2 589 600 2-s2.0-0032782383 10.1046/j.1523-1755. 1999.00566.x (Pubitemid 29353157)
4. Schambelan M., Blake S., Sraer J., Bens M., Nivez M. P., Wahbe F., Increased prostaglandin production by glomeruli isolated from rats with streptozotocin-induced diabetes mellitus. Journal of Clinical Investigation 1985 75 2 404 412 2-s2.0-0021960218 (Pubitemid 15143479)
5. Schramek H., Coroneos E., Dunn M. J., Interactions of the vasoconstrictor peptides, angiotensin II and endothelin-1, with vasodilatory prostaglandins. Seminars in Nephrology 1995 15 3 195 204 2-s2.0-0029004472
6. Chapnick B. M., Paustian P. W., Klainer E., Joiner P. D., Hyman A. L., Kadowitz P. J., Influence of prostaglandins E, A and F on vasoconstrictor responses to norepinephrine, renal nerve stimulation and angiotensin in the feline kidney. Journal of Pharmacology and Experimental Therapeutics 1976 196 1 44 52 2-s2.0-0017280093
7. Catella-Lawson F., Mcadam B., Morrison B. W., Kapoor S., Kujubu D., Antes L., Lasseter K. C., Quan H., Gertz B. J., Fitzgerald G. A., Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. Journal of Pharmacology and Experimental Therapeutics 1999 289 2 735 741 2-s2.0-0032948948 (Pubitemid 29191226)
8. Breyer M. D., Breyer R. M., Prostaglandin E receptors and the kidney. The American Journal of Physiology-Renal Physiology 2000 279 1 F12 F23 2-s2.0-0033860564 (Pubitemid 30619543)
9. Silldorff E. P., Yang S., Pallone T. L., Prostaglandin E2 abrogates endothelin-induced vasoconstriction in renal outer medullary descending vasa recta of the rat. Journal of Clinical Investigation 1995 95 6 2734 2740 2-s2.0-0028990136
10. Kvirkvelia N., McMenamin M., Chaudhary K., Bartoli M., Madaio M. P., Prostaglandin E2 promotes cellular recovery from established nephrotoxic serum nephritis in mice, prosurvival, and regenerative effects on glomerular cells. The American Journal of Physiology-Renal Physiology 2013 304 5 F463 F470 10.1152/ajprenal.00575.2012
11. Nasrallah R., Xiong H., Hébert R. L., Renal prostaglandin E2 receptor (EP) expression profile is altered in streptozotocin and B6-Ins2Akita type I diabetic mice. The American Journal of Physiology-Renal Physiology 2007 292 1 F278 F284 2-s2.0-33846221133 10.1152/ajprenal.00089.2006 (Pubitemid 46105267)
12. Makino H., Tanaka I., Mukoyama M., Sugawara A., Mori K., Muro S., Suganami T., Yahata K., Ishibashi R., Ohuchida S., Maruyama T., Narumiya S., Nakao K., Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist. Journal of the American Society of Nephrology 2002 13 7 1757 1765 2-s2.0-18444410236 10.1097/01.ASN.0000019782.37851.BF (Pubitemid 34700600)
13. Mohamed R., Jayakumar C., Ramesh G., Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6. Laboratory Investigation 2013 93 933 945 10.1038/labinvest.2013.85
14. Chen H., Charlat O., Tartaglia L. A., Woolf E. A., Weng X., Ellis S. J., Lakey N. D., Culpepper J., More K. J., Breitbart R. E., Duyk G. M., Tepper R. I., Morgenstern J. P., Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996 84 3 491 495 2-s2.0-13344259300 10.1016/S0092-8674(00)81294-5 (Pubitemid 26060722)
15. Lee G. H., Proenca R., Montez J. M., Carroll K. M., Darvishzadeh J. G., Lee J. I., Friedman J. M., Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996 379 6566 632 635 2-s2.0-0030039272 10.1038/379632a0 (Pubitemid 26053452)
16. Liu Y., Jia Z., Liu S., Downton M., Liu G., Du Y., Yang T., Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice. The American Journal of Physiology-Renal Physiology 2013 305 11 F1555 F1562 10.1152/ajprenal.00157.2013
17. Guan Y., Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. Journal of the American Society of Nephrology 2004 15 11 2801 2815 2-s2.0-16644377741 10.1097/01.ASN.0000139067.83419.46 (Pubitemid 41103389)
18. Guan Y., Yang J., Chen L., Zhang X., Zhou Y., Zhang D., Huo M., PPARs and female reproduction: evidence from genetically manipulated mice. PPAR Research 2008 2008 8 2-s2.0-44349111879 10.1155/2008/723243 723243 (Pubitemid 351727907)
19. Zheng F., Guan Y., Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy? Kidney International 2007 72 11 1301 1303 2-s2.0-36248983781 10.1038/sj.ki.5002557 (Pubitemid 350126785)
20. Miyazaki Y., Cersosimo E., Triplitt C., DeFronzo R. A., Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney International 2007 72 11 1367 1373 2-s2.0-36249006990 10.1038/sj.ki.5002516 (Pubitemid 350126770)
21. Pistrosch F., Herbrig K., Kindel B., Passauer J., Fischer S., Gross P., Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005 54 7 2206 2211 2-s2.0-21344466513 10.2337/diabetes.54.7.2206 (Pubitemid 40911285)
22. Yang J., Zhang D., Li J., Zhang X., Fan F., Guan Y., Role of PPAR γ in renoprotection in type 2 diabetes: molecular mechanisms and therapeutic potential. Clinical Science 2009 116 1 17 26 2-s2.0-60549085974 10.1042/CS20070462
23. Zhou L., Liu G., Jia Z., Yang K. T., Sun Y., Kakizoe Y., Liu M., Zhou S., Chen R., Yang B., Yang T., Increased susceptibility of db/db mice to rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters. The American Journal of Physiology-Renal Physiology 2013 305 10 F1491 F1497 10.1152/ajprenal.00004.2013
24. Jia Z., Wang H., Yang T., Microsomal prostaglandin e synthase 1 deletion retards renal disease progression but exacerbates anemia in mice with renal mass reduction. Hypertension 2012 59 1 122 128 2-s2.0-83655184681 10.1161/HYPERTENSIONAHA.111.178897
25. Paliege A., Mizel D., Medina C., Pasumarthy A., Huang Y. G., Bachmann S., Briggs J. P., Schnermann J. B., Yang T., Inhibition of nNOS expression in the macula densa by COX-2-derived prostaglandin E2. The American Journal of Physiology-Renal Physiology 2004 287 1 F152 F159 2-s2.0-2942690028 10.1152/ajprenal.00287.2003 (Pubitemid 38780594)
26. Kassi E., Pervanidou P., Kaltsas G., Chrousos G., Metabolic syndrome: definitions and controversies. BMC Medicine 2011 9, article 48 2-s2.0-79955562491 10.1186/1741-7015-9-48
27. Ninichuk V., Khandoga A. G., Segerer S., Loetscher P., Schlapbach A., Revesz L., Feifel R., Khandoga A., Krombach F., Nelson P. J., Schlöndorff D., Anders H., The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. The American Journal of Pathology 2007 170 4 1267 1276 2-s2.0-34247892356 10.2353/ajpath.2007.060937 (Pubitemid 47339334)
28. Ninichuk V., Kulkarni O., Clauss S., Anders H., Tubular atrophy, interstitial fibrosis, and inflammation in type 2 diabetic db/db mice. An accelerated model of advanced diabetic nephropathy. European Journal of Medical Research 2007 12 8 351 355 2-s2.0-34548395919 (Pubitemid 47365152)
29. Dey A., Williams R. S., Pollock D. M., Stepp D. W., Newman J. W., Hammock B. D., Imig J. D., Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria. Obesity Research 2004 12 8 1278 1289 2-s2.0-6344282521 (Pubitemid 41137472)
30. Yki-Jarvinen H., ADOPT: lessons from comparison of glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. Current Diabetes Reports 2007 7 3 173 174 2-s2.0-34250783669 10.1007/s11892-007-0028-0 (Pubitemid 46951913)
31. Sosnowski C., Janeczko-Sosnowska E., Commentary to the article: Kahn SE, Haffner SM, Heise MA, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43. Kardiologia Polska 2007 65 2 214 217
32. Kahn S. E., Haffner S. M., Heise M. A., Herman W. H., Holman R. R., Jones N. P., Kravitz B. G., Lachin J. M., O'Neill M. C., Zinman B., Viberti G., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. The New England Journal of Medicine 2006 355 23 2427 2443 2-s2.0-33845405222 10.1056/NEJMoa066224 (Pubitemid 44903747)
33. Ye H., Zhang H. J., Xu A., Hoo R. L., Resistin production from adipose tissue is decreased in db/db obese mice, and is reversed by rosiglitazone. PLoS ONE 2013 8 6 e65543 10.1371/journal.pone.0065543
34. Chodavarapu H., Grobe N., Somineni H. K., Salem E. S., Madhu M., Elased K. M., Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion. PLoS ONE 2013 8 4 e62833 10.1371/journal.pone.0062833
35. Tonelli J., Li W., Kishore P., Pajvani U. B., Kwon E., Weaver C., Scherer P. E., Hawkins M., Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 2004 53 1621 1629 (Pubitemid 38697679)
36. Galkina E., Ley K., Leukocyte recruitment and vascular injury in diabetic nephropathy. Journal of the American Society of Nephrology 2006 17 2 368 377 2-s2.0-33645454310 10.1681/ASN.2005080859
37. Furuta T., Saito T., Ootaka T., Soma J., Obara K., Abe K., Yoshinaga K., The role of macrophages in diabetic glomerulosclerosis. The American Journal of Kidney Diseases 1993 21 5 480 485 2-s2.0-0027231859 (Pubitemid 23160508)
38. Parnova R. G., Molecular mechanisms of action of prostaglandin E2 in the regulation of water osmotic permeability. Membrane and Cell Biology 2000 13 2 287 301 2-s2.0-0034084954 (Pubitemid 30184416)
39. Jia Z., Liu G., Sun Y., Kakizoe Y., Guan G., Zhang A., Zhou S. F., Yang T., mPGES-1-derived PGE2 mediates dehydration natriuresis. The American Journal of Physiology-Renal Physiology 2013 304 2 F214 F221 10.1152/ajprenal.00588.2011
40. Jia Z., Liu G., Downton M., Dong Z., Zhang A., Yang T., mPGES-1 deletion potentiates urine concentrating capability after water deprivation. The American Journal of Physiology-Renal Physiology 2012 302 8 F1005 F1012 2-s2.0-84859783515 10.1152/ajprenal.00508.2011
41. Jia Z., Aoyagi T., Kohan D. E., Yang T., mPGES-1 deletion impairs aldosterone escape and enhances sodium appetite. The American Journal of Physiology-Renal Physiology 2010 299 1 F155 F166 2-s2.0-77953846855 10.1152/ajprenal.90702.2008
42. Jia Z., Aoyagi T., Yang T., MPGES-1 protects against DOCA-salt hypertension via inhibition of oxidative stress or stimulation of NO/cGMP. Hypertension 2010 55 2 539 546 2-s2.0-74949140019 10.1161/HYPERTENSIONAHA.109. 144840
43. Jia Z., Wang H., Yang T., Mice lacking mPGES-1 are resistant to lithium-induced polyuria. The American Journal of Physiology-Renal Physiology 2009 297 6 F1689 F1696 2-s2.0-71449091915 10.1152/ajprenal.00117.2009
44. Soodvilai S., Jia Z., Wang M. H., Dong Z., Yang T., mPGES-1 deletion impairs diuretic response to acute water loading. The American Journal of Physiology-Renal Physiology 2009 296 5 F1129 F1135 2-s2.0-66049156636 10.1152/ajprenal.90478.2008
45. Flores D., Liu Y., Liu W., Satlin L. M., Rohatgi R., Flow-induced prostaglandin E2 release regulates Na and K transport in the collecting duct. The American Journal of Physiology-Renal Physiology 2012 303 5 F632 F638 10.1152/ajprenal.00169.2012